Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.
Drug Delivery Systems in the Management of Diabetes
New AACE Guidelines for Treating Type 2 Diabetes
Diabetic Kidney Disease
NICE-SUGAR: Blood Glucose Levels in the ICU
Characteristics of Gestational Diabetes
Weighing Therapeutic Diets for Type 2 Diabetics
Sodium-Glucose Transporters: A New Class of Diabetes Medications
A New Paradigm for the Treatment of Type 2 Diabetes
Do Incretins Play An Important Role In the Cardiovascular System?
The Diabetes Infrastructure: Regulation & Reimbursement
New Developments in Incretins and SGLT Inhibitors
A Resurgence of Stents
What’s Happening in Hypoglycemia?
New Treatments for Peripheral Diabetic Neuropathy
Do Herbal Remedies and Vitamins Work?
Diagnosing and Treating Peripheral Arterial Disease
The Challenges of Diagnosing Diabetes in Children
Sexual Dysfunction: Communication is the Key
Common Gastrointestinal Disorders Affecting Diabetics
The Link Between Diabetes and Sleep Apnea
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video